Core Viewpoint - A securities class action lawsuit has been filed against BioAge Labs, Inc. for alleged misleading statements related to its IPO and clinical trials [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased BioAge stock during the IPO on September 26, 2024, with a lead plaintiff deadline set for March 10, 2025 [1]. - Allegations include that BioAge's registration statement and prospectus contained false or misleading statements regarding the STRIDES Phase 2 trial for azelaprag, specifically concerning liver transaminitis and safety concerns [2]. Group 2: Lead Plaintiff Process - Investors can seek to be appointed as a lead plaintiff representative by March 10, 2025, or remain absent class members [3]. - The lead plaintiff will represent the interests of all class members and select counsel for the litigation [3]. Group 3: Law Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4].

Core Viewpoint - BioAge Labs, Inc. is facing a class action lawsuit due to alleged violations of the Securities Act of 1933 related to its IPO, with claims that the offering documents were misleading regarding safety concerns and clinical trial expectations [1][3]. Group 1: Class Action Lawsuit Details - The class action lawsuit, titled Soto v. BioAge Labs, Inc., allows purchasers of BioAge Labs stock from its IPO on September 26, 2024, to seek lead plaintiff status by March 10, 2025 [1][5]. - BioAge Labs sold 12.65 million shares at $18.00 per share during its IPO [2]. - The lawsuit alleges that the IPO documents falsely indicated no safety concerns and optimistic expectations for the STRIDES clinical trial [3]. Group 2: Impact of Clinical Trial Results - On December 6, 2024, BioAge Labs announced the discontinuation of the STRIDES Phase 2 study due to liver transaminitis observed in subjects, leading to a stock price drop of over 76% [4]. - By the time the class action lawsuit commenced, BioAge Labs stock was trading around $5.82 per share, significantly lower than the IPO price of $18.00 [4]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in this class action lawsuit and has a strong track record in securities fraud cases, having recovered $6.6 billion for investors in related cases [6].

NEW YORK, March 5, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or traceable to the registration statement for BioAge's initial public offering conducted on September 26, 2024 (the "IPO"), of the important March 10, 2025 lead plaintiff deadline.So what: If you purchased BioAge stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrange ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against BioAge Labs, Inc. due to alleged violations of federal securities laws related to misleading information about its STRIDES Phase 2 clinical trial [2][4]. Group 1: Company Overview - BioAge Labs, Inc. (NASDAQ: BIOA) completed its initial public offering on September 27, 2024, selling 12.65 million shares at $18 per share, including an additional 1.65 million shares purchased by underwriters [4]. - The company faced significant stock price decline following the announcement on December 6, 2024, that it would discontinue the STRIDES Phase 2 study of its drug candidate azelaprag due to liver transaminitis observed in subjects [5][6]. Group 2: Legal Proceedings - A federal securities class action has been filed against BioAge, with a deadline of March 10, 2025, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest who directs and oversees the litigation on behalf of the class [7]. Group 3: Investor Communication - Faruqi & Faruqi encourages investors who suffered losses in BioAge to contact them directly to discuss legal options [1][8]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding BioAge's conduct [8].

NEW YORK, March 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioAge Labs, Inc. (NASDAQ: BIOA).Shareholders who purchased shares of BIOA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE: https://securitiesclasslaw.com/securities/bioage-labs-inc-loss-submission-form/?id=132952&from=4 CLASS PERIOD: This lawsuit is o ...

Core Viewpoint - The Therapeutic Goods Administration (TGA) of Australia has declined the approval of lecanemab for early Alzheimer's disease, which is a setback for patients and healthcare professionals in Australia [1][3]. Company Summary - BioArctic AB, in collaboration with Eisai, developed lecanemab, which is a humanized monoclonal antibody targeting amyloid-beta (Aβ) aggregates [9][14]. - BioArctic has the right to commercialize lecanemab in the Nordic region and is preparing for joint commercialization with Eisai [7][13]. - The company has no development costs for lecanemab and is entitled to payments related to regulatory approvals and sales milestones [13][14]. Industry Summary - Alzheimer's disease (AD) is the most common cause of dementia, accounting for 60-70% of cases, with a significant unmet need for effective treatments [4]. - The number of people living with dementia in Australia is projected to increase from approximately 411,000 in 2023 to about 849,000 by 2058 [4]. - Lecanemab has been approved in 11 markets, including the U.S., Japan, and the UK, and is based on positive Phase 3 clinical trial results [6][10].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased BioAge Labs, Inc. stock during its IPO on September 26, 2024, about the March 10, 2025, deadline to become a lead plaintiff in a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought BioAge stock may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must act by March 10, 2025, to serve as lead plaintiff [3][8]. Group 2: Background of the Case - The lawsuit claims that BioAge misrepresented the safety and efficacy of its lead product candidate, azelaprag, in relation to the STRIDES clinical trial, which was expected to yield topline results in 2025 [5]. - BioAge's collaboration with Eli Lilly's Chorus clinical development organization was highlighted, suggesting a robust trial design and execution [5]. - The company discontinued the STRIDES Phase 2 study after subjects exhibited elevated liver enzyme levels, indicating potential organ damage, which was not disclosed in prior trials [6]. Group 3: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, noting its own history of successful settlements [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - A securities class action lawsuit has been filed against BioAge Labs, Inc. for alleged misleading statements related to its IPO and clinical trials [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased BioAge stock during the IPO period around September 26, 2024 [1]. - The lead plaintiff deadline for the lawsuit is set for March 10, 2025 [1][3]. Group 2: Allegations Against Defendants - The complaint alleges that BioAge's registration statement and prospectus contained false or misleading statements regarding the STRIDES Phase 2 trial for azelaprag [2]. - Specific allegations include failure to disclose the potential for liver transaminitis in previous clinical trials and preclinical studies [2]. - It is claimed that BioAge misrepresented the safety concerns and expected outcomes of the STRIDES clinical trial, leading to materially false statements about the company's business and prospects [2]. Group 3: Lead Plaintiff Process - Investors can seek to be appointed as a lead plaintiff representative by the March 10, 2025 deadline, or they can choose to remain absent class members [3]. - The lead plaintiff will represent the interests of all class members and select counsel for the litigation [3]. Group 4: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4]. - The firm encourages affected BioAge investors to contact them for more information regarding the lawsuit [4].

Core Viewpoint - A securities class action lawsuit has been filed against BioAge Labs, Inc. for alleged misleading statements related to its IPO and clinical trials [1]. Group 1: Allegations Against BioAge - The lawsuit claims that BioAge made false and misleading statements in its registration statement and prospectus regarding the STRIDES Phase 2 trial for azelaprag [3]. - Specific allegations include the failure to disclose the potential for liver transaminitis in previous clinical trials and preclinical studies [3]. - The complaint asserts that BioAge misrepresented safety concerns and the expected outcomes of the STRIDES clinical trial, leading to materially false and misleading statements about the company's business and prospects [3]. Group 2: Legal Process for Investors - Investors in BioAge have until March 10, 2025, to seek appointment as lead plaintiff in the class action lawsuit [4]. - A lead plaintiff represents the interests of all class members and typically has the largest financial stake in the case [4]. - Investors can choose to participate actively or remain absent from the proceedings without affecting their ability to recover any potential damages [4].

Core Viewpoint - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has reaffirmed its positive opinion for lecanemab (Leqembi®), which is a significant step towards the marketing authorization decision by the European Commission (EC) for the treatment of early Alzheimer's disease [1][2]. Group 1: Lecanemab Overview - Lecanemab is an anti-Aβ monoclonal antibody that targets both toxic protofibrils and Aβ plaques, which are associated with neuronal injury in Alzheimer's disease [3]. - The drug is already approved in multiple markets including the U.S., Japan, China, and the UK, and if approved by the EC, it will be available across all 27 EU member states as well as Iceland, Liechtenstein, and Norway [4][7]. Group 2: Regulatory Process - The EC requested additional safety information regarding lecanemab after the initial CHMP opinion in November 2024, but the CHMP concluded that no update to its positive opinion was necessary [2]. - A supplemental Biologics License Application (sBLA) for less frequent intravenous maintenance dosing was approved by the U.S. FDA in January 2025, and a rolling submission for a subcutaneous auto-injection formulation is underway with a PDUFA date set for August 31, 2025 [8]. Group 3: Clinical Trials and Research - Eisai's Phase 3 clinical study (AHEAD 3-45) with lecanemab in individuals with preclinical Alzheimer's disease is ongoing and was fully recruited in October 2024 [9]. - The Tau NexGen clinical study for Dominantly Inherited Alzheimer's Disease (DIAD) is also ongoing and includes lecanemab as a key therapy [10]. Group 4: Collaboration and Commercialization - BioArctic has a long-term collaboration with Eisai for the development and commercialization of lecanemab, with Eisai responsible for clinical development and market approval [11]. - BioArctic retains rights to commercialize lecanemab in the Nordic region and is preparing for its commercialization in collaboration with Eisai [11][12].